Arndt Vogel: Interesting Analysis on Potential Biomarkers to Guide Adjuvant Treatment
Arndt Vogel, Head of the Visceral Oncology Center, Head of the Center for Personalized Medicine, MHH, and Senior Consultant of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, shared a post on X:
“Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma
Post-hoc STAMP phase 2 trial of adjuvant GemCis
Interesting analysis on potential biomarkers to guide adjuvant treatment.”
Title: Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma
Authors: Hyehyun Jeong, Ji-Hye Oh, Hee-Sung Ahn, Baek-Yeol Ryoo, Kyu-pyo Kim, Jae Ho Jeong, Inkeun Park, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Woohyung Lee, Ki-Hun Kim, Deog-Bog Moon, Gi Won Song, Dong-Hwan Jung, Seung-Mo Hong, Chae Won Park, In-Pyo Baek, You Sook Cho, Kyunggon Kim, Chang Ohk Sung, Changhoon Yoo
More posts featuring Arndt Vogel on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023